New FDA Approval: Subcutaneous Testosterone Pen

The FDA has now approved the first subcutaneous testosterone auto-injector pen (Xyosted) for symptomatic patients with low testosterone levels. It is self-administered once weekly and is available in three doses: 50 mg, 75 mg, and 100 mg. The recommended starting dose is 75 mg per week.